Which cancers is mirvetuximab soravtansine (Elahere) approved to treat, and in which adult patients?

Mirvetuximab soravtansine (Elahere) is indicated as monotherapy for adults with folate receptor-alpha (FRα)-positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens.